重视口服依曲康唑治疗妇科真菌感染时药物相互作用  

To focus on the interaction of oral itraconazole in the treatment of gynecology fungi infection

作　　者：左俊姣[1] 谭蓉[2] 

机构地区：[1]广东省珠海市妇幼保健院,519000 [2]贵州省贵阳医学院附属医院

出　　处：《中国现代药物应用》2007年第3期25-26,共2页Chinese Journal of Modern Drug Application

摘　　要：目的促进临床联合用药合理性水平的提高。方法根据依曲康唑对CYP3A4的抑制作用,影响其底物药物吸收和代谢过程,探讨联合用药的药物相互作用。结果依曲康唑通过抑制肠道CYP3A4作用可降低口服底物药物的首过效应,提高底物药物的生物利用度、抑制肝微粒体CYP3A4,使底物药物体内代谢受阻等途径,导致底物药物血药浓度升高、半衰期延长,从而增加阿普唑仑、辛伐他汀等药物A-型药物不良反应的风险。结论医院医药专业人员应重视联合用药中依曲康唑导致潜在的药物不良反应风险。Objective To provide references for the rational used medicine in clinic.Methods Itraconazole is a inhibitor of the cytochrome P450(CYP)3A4 enzyme,which influence its substrate absorption and metabolism.Drug-drug interactions are considerable problem in clinical practice such as itraconazole is needed to better understand.Results Itraconazole inhibit the intestinal CYP3A4,the presystemic metabolism and bioavailability of orally the substrates may are reduced and increased respectively.Itraconazole inhibit the hepatic microsome CYP3A4 and causes the substrates in vivo metabolism to be blocked,to increases the plasma concentrations and to lengthen the half live of that.The risk of A-ADRs of alprazolam or simvastatin are increased when coadministered with itraconazole.Conclusion The hospital medicine specialist should regard the risk of potential ADR of drugs when coadministered with itraconazole.

关 键 词：依曲康唑 CYP3A4 药物相互作用 药物不良反应 

分 类 号：R711.3[医药卫生—妇产科学] R969.2[医药卫生—临床医学]